- Home
- ETON vs PEO Comparison
ETON vs PEO Comparison
Compare ETON & PEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ETON | PEO |
|---|---|---|
| Founded | 2017 | 1929 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 510.1M | 570.8M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | ETON | PEO |
|---|---|---|
| Price | $23.04 | $27.55 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $39.33 | N/A |
| AVG Volume (30 Days) | ★ 337.4K | 73.6K |
| Earning Date | 03-19-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 5.93% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $79,950,000.00 | N/A |
| Revenue This Year | $34.30 | N/A |
| Revenue Next Year | $36.43 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 104.94 | N/A |
| 52 Week Low | $11.09 | $18.35 |
| 52 Week High | $23.00 | $27.25 |
Technical Indicators
Market Signals| Indicator | ETON | PEO |
|---|---|---|
| Relative Strength Index (RSI) | 75.33 | 69.27 |
| Support Level | $16.23 | $21.14 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 1.13 | 0.54 |
| MACD | 0.53 | 0.01 |
| Stochastic Oscillator | 86.94 | 88.21 |
Price Performance
Historical ComparisonAbout ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
About PEO Adams Natural Resources Fund Inc.
Adams Natural Resources Fund Inc is a non-diversified U.S. equity fund that invests in liquid energy and other natural resources stocks. The Fund's investment objectives are preservation of capital, reasonable income, and opportunity for capital gain. A majority of its assets are invested in petroleum or natural resources industries or industries connected to them. It has broad flexibility to invest in stocks of varying capitalizations and predominantly invests in stocks found in the S&P 500 Energy and S&P 500 Materials sectors.